LTF and cancer: However, a concomitant variation in these biomarkers was observed post Cisplatin, TiNPs-cisplatin and lactoferrin-cisplatin, doxorubicin, TiNPs-doxorubicin, lactoferrin-doxorubicin and Neupogen treatment with TiNPs-cisplatin and TiNPS-doxorubicin elucidating the most significant influence with a mean value of 11.5 and 12, respectively, reflecting the superiority of these drug-delivery systems in targeting cancer cells and reducing the disease impact (Figure 5).